Cancer Research UK Centre for Drug Development

Cancer Research UK's Centre for Drug Development is the partner of choice for early-phase cancer drug development. Through clinical development collaborations with Cancer Research Horizons, the academic and biopharma sectors across the globe can access its unique infrastructure to realise the full potential of their research.

Scientist working in a lab looking at a test tube.

>30

years of experience

~20

agents under active development

6

agents registered as medicines to date

Why work with the Centre for Drug Development?

With a team of over 100 drug development scientists and operational staff, their expertise spans preclinical and medical sciences, regulatory affairs, quality assurance, project management, drug safety, clinical operations and data management.

Their goal is to see scientific breakthroughs bring benefits to patients sooner. Priority targets include:

First-in-class therapies
First-in-human clinical trials

Find out more

News from the Centre for Drug Development

Cancer Research UK partners with ORIC Pharmaceuticals to bring first-in-class CIP2A-targeted therapy into clinical trials

Cancer Research UK have signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.

Cancer Research UK and partners announce new global Phase 2 trial in rare adrenal gland cancer

Cancer Research UK launches a new Phase 2 clinical trial for people with advanced adrenocortical carcinoma, a rare and aggressive cancer.

Hundreds of cancer patients to benefit from improved access to genetic testing

Cancer Research UK, The Royal Marsden and Guardant Health will make hundreds of genetic tests available to provide personalised cancer care across the UK.